Clinical Trial Update: This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population [Phase 4]

View source ↗

Summary

Phase 4 study evaluating safety and immunogenicity of Ixiaro (IC51) in an elderly population has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• IXIARO (inactivated Japanese encephalitis vaccine)

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Japanese Encephalitis | Phase 4 | Status: COMPLETED